INTRODUCTION
============

A substantial body of evidence indicates, that low-grade inflammation in the vascular endothelium promotes atherogenesis \[[@B1], [@B2]\]. This is indirectly evidenced by the fact that several inflammatory markers are linked to an increased risk of atherosclerosis. High-sensitive CRP (hsCRP) has been reported to associate with an increased risk of myocardial infarction, stroke, sudden death from cardiac causes, and peripheral arterial disease \[[@B3]\]. In addition, hsCRP has been shown to predict the first cardiovascular event better than low-density lipoprotein cholesterol (LDL-C) \[[@B3]\].

Recruitment of inflammatory cells from the circulation and their transendothelial migration is one of the earliest phases of atherogenesis \[[@B3]\]. Vascular endothelium expresses cellular adhesion molecules (CAMs) in response to several inflammatory stimuli \[[@B4]\]. The evidence for the role of CAMs in the pathogenesis of atherosclerosis has emerged from experimental studies which have demonstrated the focal expression of adhesion molecules in atherosclerotic plaques \[[@B4]--[@B6]\].

Different CAMs have various functions in the vasculature. Selectins and their ligands are involved in the first steps in leukocyte adhesion at sites of endothelial injury as they mediate the rolling and tethering of leukocytes in the vascular wall \[[@B1], [@B2]\]. Intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) induce firm adhesion of inflammatory cells to the vascular surface \[[@B3]\]. Overall, both soluble ICAM-1 (sICAM-1) and soluble VCAM-1 (sVCAM-1) have been linked to increase risk of atherosclerosis \[[@B7]--[@B9]\].

Apolipoprotein E (apoE) is secreted from hepatocytes and macrophages. ApoE is transported in lipoproteins, and it regulates the hepatic uptake of remnant lipoproteins and facilitates cholesterol efflux from foam cells \[[@B10]\]. In addition, apoE has a central role in inflammation and in mediating the central nervous system response to injury \[[@B11]--[@B13]\]. There are three common ApoE isoforms, designated E2, E3, and E4, which are encoded for by distinct alleles on human chromosome 19. ApoE isoforms are distributed in six different phenotypes E2/2, E2/3, E3/3, E4/2, E4/3, and E4/4 \[[@B10]\]. The presence of E4 isoform is associated with coronary heart disease \[[@B14]\] and with the early onset of Alzheimer\'s disease \[[@B15]\].

So far, there are sparse data on apoE polymorphism in relation to the parameters of inflammation. Mänttäri et al \[[@B16]\] showed that dyslipidemic men with E4/4, E4/3, and E4/2 phenotypes exhibit lower CRP values than men carrying other apoE phenotypes. In a recent report by März et al \[[@B17]\], carriers of apoE2 allele and apoE3/3 homozygotes had significantly higher CRP than individuals with the genotypes apoE3/4 and apoE4/4. In dyslipidemic men and women, C-reactive protein has been reported to be lower in subjects with one or two copies of E4 allele than in those with zero E4 allele \[[@B18]\]. Paradoxically, E4 allele has been associated with an enhanced inflammatory reaction after cardiopulmonary bypass \[[@B19]\]. In line, transgenic mice expressing the E4 allele had greater systemic and brain elevations of proinflammatory cytokines than E3 carriers \[[@B20]\].

We hypothesize that the apoE phenotype, as a critical component in inflammatory processes, may influence the levels of inflammation markers. HDL has been demonstrated to exhibit antiinflammatory properties by inhibiting cytokine induced expression of adhesion molecules \[[@B21]--[@B23]\]. In contrast, acute inflammation process may decrease HDL concentration and thus compromise its antiatherogenic function \[[@B24], [@B25]\]. Interestingly, recycling of apoE is closely linked to HDL metabolism \[[@B26]\]. Therefore we studied the effects of apoE phenotype on the levels of CRP and sCAMs on a sample of Finnish low-HDL families and in normolipidemic subjects.

SUBJECTS AND METHODS
====================

The study subjects were recruited according to the study protocol as reported previously \[[@B27]\]. To identify the low-HDL families, first degree relatives of the probands were examined. The family members were coded as affected if their HDL-C levels were below the 10th percentile cut-off levels. If at least two affected subjects were identified in the family, all available second-degree relatives and spouses were contacted and included in the study. The blood samples for the lipid and lipoprotein analysis were taken at the same visit as the inflammation parameters and therefore the lipid and lipoprotein values in this study represent the values of that visit, and not those of the screening visit. Altogether 211 low-HDL family members and 157 normolipidemic subjects had measures of their apoE phenotype, hsCRP, and sVCAM-1 concentrations. Seventeen low-HDL subjects had history of CHD. The normolipidemic group comprised healthy volunteers and normolipidemic spouses from the low-HDL families. They were required to have no signs of CHD or diabetes, and no lipid lowering medication. The smoking status of the patients was categorized into current smokers and nonsmokers (including exsmokers). Hypertension was defined as self-reported use of antihypertensive drugs, systolic blood pressure ≥ 140 mmHg, or diastolic blood pressure ≥ 90 mmHg. Estrogen use was defined as any means of estrogen administration (oral contraceptives, or oral or transdermal postmenopausal hormone replacement therapy). Venous blood samples were collected after overnight fasting. Serum was separated and used for the biochemical measurements. Lipid and lipoprotein measurements were done from serum as described previously \[[@B27]\]. Serum levels of sICAM-1, sVCAM-1, and sE-selectin were measured by using commercially available monoclonal antibody-based ELISAs (R & D Systems, Minneapolis, MN, USA). Serum highly sensitive CRP (hsCRP) was determined by a commercial kit from Medix Biochemica, Kauniainen, Finland. Subjects with CRP levels over 10 mg/l were excluded. ApoE phenotype was determined by the method of Havekes et al \[[@B28]\]. Statistical comparisons of clinical and biochemical parameters were performed with SPSS 11.0 for Windows (SPSS Inc., Chigaco, IL, USA). Data are expressed as mean ± standard error of mean (SEM). Continuous variables were compared between two groups by Student *t* test. Variables with nonnormal distribution were ${\log}_{10}$-transformed before comparison. *P* \< .05 was considered to be significant (two-tailed). The frequency distribution between the groups was compared with the Chi-square test. The correlation coefficients between the biochemical and clinical characteristics were examined by Pearson\'s correlation for continuous variables. Multiple regression analysis was performed to determine the relative contribution of different variables to hsCRP and sVCAM-1 values. In the low-HDL group, the subjects came from 47 different families. Ten families had only one subject, and five families had 11--16 subjects. Because the subjects in the present cohort were not independent, we used the family number (which indicates belonging to a certain family) as a random variable. Family-number-adjusted residuals of log CRP and log VCAM were used in the multiple regression model for low-HDL family members. Since control subjects were not related, the family-number adjustment was performed only in the low-HDL group.

RESULTS
=======

The effects of apoE phenotype was studied by dividing subjects into two subgroups (apoE groups): into the E3 group, which included E3/2 and E3/3 phenotypes, and into the E4 group which included E4/2, E4/3, and E4/4 phenotypes. Clinical and biochemical characteristics of the study subjects are presented in [Table 1](#T1){ref-type="table"}.

[Table 2](#T2){ref-type="table"} shows that serum hsCRP values were significantly lower in the E4 than in the E3 subgroup both in the low-HDL group (*P* \< .01) and in the normolipidemic group (*P* \< .05) after adjustment for age, BMI, serum apoA-I, apoA-II, apoB, HDL-C, LDL-C, triglycerides, smoking status, hypertension, and gender in normolipidemic subjects, and after additional adjustment for family number in the low-HDL group. The concentration of serum sVCAM-1 was significantly lower in the E4 group than in the E3 group in low-HDL subjects (*P* \< .01) but the significance disappeared after adjustment for family number ([Table 2](#T2){ref-type="table"}). Multiple regression analysis revealed that apoE phenotype was a significant predictor of serum hsCRP values both in low-HDL and normolipidemic subjects (*P* = .023 and *P* = .011, resp) ([Table 3](#T3){ref-type="table"}). Estrogen used was also a strong predictor of serum hsCRP concentration in low-HDL subjects (*P* = .026) as well as in normolpidemic subjects (*P* = .036) ([Table 3](#T3){ref-type="table"})

DISCUSSION
==========

The major finding of the present study is that subjects presenting the apoE4 allele have decreased levels of serum hsCRP. This is an interesting observation, since ApoE plays a central role in inflammation and atherosclerosis. ApoE knockout mice are especially prone to atherosclerosis \[[@B10]\] and to die from lipopolysaccharide (LPS)-induced sepsis \[[@B11]\]. ApoE participates in cholesterol efflux, and has been observed to be recycled from triglyceride-rich lipoproteins into HDL-particles \[[@B10], [@B26]\]. In mice, exogenous apoE injection has been demonstrated to decrease the LPS-induced production of proinflammatory cytokines, probable by decreasing the release of cytokines from macrophages, which was accompanied by reduced mortality \[[@B11]\]. CRP and apoE concentrations are inversely related in obese patients \[[@B12]\]. In addition, human CRP transgene expression has been shown to cause accelerated atherosclerosis in apolipoprotein E-deficient mice \[[@B13]\]. Thus, according to these studies, the role of apoE in inflammation and atherosclerosis may be protective.

Despite the importance of apoE in the inflammatory process, only few studies have linked apoE polymorphisms to inflammatory parameters. In the central nervous system, apoE4 has been reported to be less effective than apoE3 or apoE2 at suppressing the activation of microglia in cell culture models of brain inflammation \[[@B29]\]. Transgenic mice expressing the apoE4 allele have significantly greater systemic and brain elevations of proinflammatory cytokines TNF-alpha and IL-6 as compared with their apoE3 counterparts \[[@B20]\]. In the present study, the hsCRP concentration was significantly lower in subjects exhibiting apoE4 allele than in those exhibiting other alleles. Likewise, Mänttäri and associates demonstrated, in a population of 179 dyslipidemic Finnish men, that subjects with apoE4/3 phenotype had lower mean CRP concentration than those with apoE3/3 phenotype \[[@B16]\]. In Japanese Americans, CRP values have been reported to be significantly higher in apoE2 carriers than in apoE3 or apoE4 carriers, and similar between apoE3 and apoE4 carriers \[[@B30]\]. In line with the Japanese data, German patients with or without coronary heart disease also showed higher CRP values in apoE2 carriers than in apoE3/4 heterozygotes or in apoE4/4 homozygotes \[[@B17]\]. However, CRP was also significantly higher in apoE3/3 homozygotes than in apoE3/4 heterozygotes or in apoE4/4 homozygotes \[[@B17]\]. Similarly, in the Cardiovascular Health Study \[[@B31]\], CRP values were lower in apoE4 positive than in apoE4 negative individuals independently of the amount of used alcohol. Thus, the present data extend these previous observations to a cohort of low-HDL family members as well as to normolipidemic subjects.

The mechanisms behind low serum CRP values in apoE4 carriers in this study, and in previous works \[[@B16]--[@B18], [@B31]\] are unclear. Since apoE phenotype remained as a predictor of hsCRP in multiple regression model, the difference between apoE4 and apoE3 groups can not be explained by confounding factors, such as estrogen use. One explanation, originally suggested by März and associates \[[@B17]\], could be that the metabolism of CRP is related to mevalonate pathway. In carriers of apoE4, the mevalonate pathway may be down-regulated resulting in decreased CRP \[[@B17]\].

The observed low serum CRP values in apoE4 carriers in the present study, and reportedly low CRP values in apoE4 carriers in previous works \[[@B16]--[@B18], [@B31]\], are perplexing findings since apoE4 allele is associated to an increased risk of atherosclerosis \[[@B14]\]. However, in the present study, the low-HDL family members within the E4 group had an atherogenic lipid profile: they had higher concentrations of apoB, a trend for higher serum triglycerides, and lower concentration of HDL-C as compared with the E3 group. Thus, the changes in lipoproteins rather than changes in inflammatory parameters may explain the atherogenity of apoE4 allele.

We conclude that apoE phenotype has a strong influence on C-reactive protein. ApoE may be a double-faced protein having different actions in lipid metabolism and inflammation.
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Figures and Tables
==================

###### 

The clinical characteristics and lipid values of the study subjects.

  -------------------------- ---------------------------- -------------------------------------------- ------------- -------------
                             Low-HDL subjects *n* = 211   Normolipidemic subjects *n* = 157                          
                                                                                                                     
                             E3 group                     E4 group                                     E3 group      E4 group
                             *N* = 140                    *N* = 71                                     *N* = 101     *N* = 56
  AGE (y)                    41.5 ± 1.2                   41.5 ± 1.8                                   51.8 ± 1.1    49.3 ± 1.8
  BMI (kg/m2)                25.6 ± 0.3                   25.6 ± 0.5                                   24.9 ± 0.4    24.3 ± 0.4
  Gender (male/female)       68/72                        41/30                                        45/56         25/31
  Smokers (%)                17.1%                        31.0%[\*](#TF1){ref-type="table-fn"}         18.8%         16.1%
  Hypertension(%)            27.1%                        22.5%                                        27.7%         17.9%
  Estrogen use(%)            17.1%                        18.3%                                        15.8%         19.6%
  Cholesterol (mmol/l)       5.05 ± 0.07                  5.27 ± 0.13                                  5.05 ± 0.08   5.13 ± 0.11
  Triglycerides (mmol/l)     1.32 ± 0.06                  1.53 ± 0.09                                  1.05 ± 0.08   0.95 ± 0.04
  HDL-cholesterol (mmol/l)   1.30 ± 0.04                  1.14 ± 0.04[\*](#TF1){ref-type="table-fn"}   1.51 ± 0.04   1.51 ± 0.05
  LDL-cholesterol (mmol/l)   3.15 ± 0.08                  3.43 ± 0.12                                  3.07 ± 0.07   3.19 ± 0.10
  ApoA-I (mg/dl)             136 ± 2                      129 ± 2                                      147 ± 3       145 ± 3
  ApoA-II (mg/dl)            36 ± 1                       36 ± 1                                       37 ± 1        37 ± 1
  ApoB (mg/dl)               98 ± 2                       106 ± 3[‡](#TF1){ref-type="table-fn"}        91 ± 2        91 ± 2
  -------------------------- ---------------------------- -------------------------------------------- ------------- -------------

Data are expressed as means ± SEMs.

\**P* \< .05, ^‡^*P* \< .06 after adjustment for smoking.

###### 

The concentrations of hsCRP, sVCAM-1, sICAM-1, and sE-SELECTIN in Low-HDL subjects and normolipidemic subjects divided by apoE subgroups.

  --------------------- ---------------------------- ---------------------------------------------- -------------------- --------------------------------------------
                        Low-HDL subjects *n* = 211   Normolipidemic subjects *n* = 157                                   
                                                                                                                         
                        E3 group *n* = 140           E4 group *n* = 71                              E3 group *n* = 101   E4 group *n* = 56
                                                                                                                         
  CRP (mg/l)            1.72 ± 0.16                  1.14 ± 0.17[\*\*](#TF2){ref-type="table-fn"}   1.29 ± 0.14          0.63 ± 0.08[\*](#TF2){ref-type="table-fn"}
  sVCAM-1 (ng/ml)       540 ± 11                     478 ± 12                                       496 ± 10             494 ± 13
  sICAM-1 (ng/ml)       234 ± 5                      238 ± 7                                        223 ± 6              236 ± 5
  sE-selectin (ng/ml)   49 ± 2                       50 ± 2                                         45 ± 2               50 ± 8
  --------------------- ---------------------------- ---------------------------------------------- -------------------- --------------------------------------------

Data are expressed as means ± SEMs. \*\**P* \< .01; \**P* \< .05 for the comparison with the E3 group after adjustment for age, gender, BMI, hypertension, smoking status, and lipoprotein variables; and family number in the low-HDL group.

###### 

Multiple regression analysis of predictors of CRP values in low-HDL and normolipidemic subjects.

  ---------------- ------------------ ------------------------- ---------------- ---------
                   Low-HDL subjects   Normolipidemic subjects                    
                                                                                 
  Variable         Standardized β     *P*                       Standardized β   *P*
  Age              +0.147             .080                      +0.244           .003
  BMI              +0.339             \< .001                   +0.315           \< .001
  Smoking status   +0.129             .057                      −0.027           .703
  Hypertension     +0.024             .732                      +0.000           .997
  Gender           +0.092             .230                      −0.154           .878
  LDL-C            −0.013             .899                      +0.064           .524
  Triglycerides    +0.106             .410                      +0.119           .246
  HDL-C            +0.082             .620                      +0.204           .173
  ApoA-I           +0.008             .961                      +0.260           .062
  ApoA-II          −0.086             .384                      +0.062           .473
  ApoB             +0.057             .676                      −0.031           .789
  Estrogen use     +0.166             .026                      +0.161           .036
  ApoE grouping    −0.150             .023                      −0.178           .011
  ---------------- ------------------ ------------------------- ---------------- ---------

The adjusted multiple *R*^2^ is 0.202 (*P* \< .001) for low-HDL subjects and 0.326 (*P* \< .001) for normolipidemic subjects when all variables are included. The dependent variable in low-HDL family members is the family number adjusted residual of log CRP, and in normolipidemic subjects, the dependent variable is log CRP. Variables with skewed distribution were log-transformed before entering into the model.
